We are live on ! Find out more
APTO

Aptose Biosciences, Inc.
APTO

Delisted

APTO was delisted on the 1st of April, 2025.

Back to rankings

58 hedge funds and large institutions have $42.6M invested in Aptose Biosciences, Inc. in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more call options, than puts

Call options by funds: $197K | Put options by funds: $102K

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 64 → 58 (-6)

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

50% less capital invested

Capital invested by funds: $85.8M → $42.6M (-$43.3M)

Holders
58
Holders Change
-6
Holders Change %
-9.38%
% of All Funds
0.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
22
Reduced
14
Closed
17
Calls
$197K
Puts
$102K
Net Calls
+$95K
Net Calls Change
+$214K

Top Buyers

Rank Fund Capital Flow
1
CC
Carlson Capital
Texas
+$1.42M
2
SMH
Sanders Morris Harris
Texas
+$1.23M
3
VC
Voss Capital
Texas
+$1.01M
4
Two Sigma Investments
Two Sigma Investments
New York
+$982K
5
Millennium Management
Millennium Management
New York
+$833K

Top Sellers

Rank Fund Capital Flow
1
FLAM
First Light Asset Management
Minnesota
-$9M
2
CAM
Cormorant Asset Management
Massachusetts
-$6.54M
3
O
OrbiMed
New York
-$5.66M
4
6CM
683 Capital Management
New York
-$2.28M
5
OM
Opaleye Management
Massachusetts
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
26
Cubist Systematic Strategies
Connecticut
$92K +$141K +150 New
GS
27
Gagnon Securities
New York
$79K -$1.88K -2 -2%
BCM
28
Bayesian Capital Management
New York
$51K +$78.9K +84 New
UBS Group
29
UBS Group
Switzerland
$48K +$35.7K +38 +93%
CA
30
Cetera Advisors
Colorado
$44K +$42.3K +45 +167%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$43K – – –
US Bancorp
32
US Bancorp
Minnesota
$41K – – –
Toronto Dominion Bank
33
Toronto Dominion Bank
Ontario, Canada
$38K +$54.5K +58 +1,160%
EP
34
Equius Partners
California
$34K +$52.6K +56 New
TCBWMS
35
Texas Capital Bank Wealth Management Services
Texas
$34K +$52.6K +56 New
TCA
36
Transcend Capital Advisors
New Jersey
$32K – – –
VF
37
Virtu Financial
New York
$31K +$47.9K +51 New
Rockefeller Capital Management
38
Rockefeller Capital Management
New York
$29K +$42.3K +45 +1,500%
BFEC
39
Benjamin F. Edwards & Company
Missouri
$27K – – –
Squarepoint
40
Squarepoint
New York
$27K +$9.4K +10 +29%
RJA
41
Raymond James & Associates
Florida
$22K -$8.46K -9 -20%
NFSG
42
Newbridge Financial Services Group
Florida
$20K – – –
WA
43
WealthTrust Axiom
Pennsylvania
$20K – – –
NDSI
44
Newman Dignan & Sheerar Inc
Rhode Island
$19K +$1.88K +2 +7%
HF
45
HRT Financial
New York
$17K +$27.3K +29 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$16K -$9.4K -10 -29%
FDCDDQ
47
Federation des caisses Desjardins du Quebec
Quebec, Canada
$15.6K +$21.6K +23 +767%
Wells Fargo
48
Wells Fargo
California
$15K -$30.1K -32 -57%
KAS
49
Kestra Advisory Services
Texas
$15K +$22.6K +24 New
BFM
50
Boothbay Fund Management
New York
$14K – – –
1
2
3

APTO Hedge Fund Activity: Q4 2021 in Review

58 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2021, worth a combined $42.6M — down 50% from $85.8M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of APTO and 11 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 22 added.

The largest buyer was Carlson Capital, adding an estimated $1.42M. The largest seller was First Light Asset Management, exiting entirely with an estimated $9M sold.

  • 58 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2021, down from 64 in Q3 2021.
  • Funds reported $42.6M of Aptose Biosciences, Inc. stock for Q4 2021, down 50% quarter-over-quarter.
  • 11 funds opened new Aptose Biosciences, Inc. positions in Q4 2021 and 17 closed out, a net change of -6 holders.
  • The largest Aptose Biosciences, Inc. buyer in Q4 2021 was Carlson Capital, an estimated $1.42M added.
  • The largest Aptose Biosciences, Inc. seller in Q4 2021 was First Light Asset Management, an estimated $9M sold.

Based on aggregated 13F filings for Q4 2021.